Edition:
United Kingdom

Advaxis Inc (ADXS.OQ)

ADXS.OQ on NASDAQ Stock Exchange Global Select Market

1.45USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
159,725
52-wk High
$7.42
52-wk Low
$1.16

Select another date:

Mon, Apr 23 2018

BRIEF-Advaxis Announces Executive Leadership Changes

* ADVAXIS INC - KENNETH BERLIN HAS BEEN APPOINTED AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Advaxis Reports Q1 Loss Per Share $0.49

* ADVAXIS REPORTS FISCAL 2018 FIRST QUARTER FINANCIAL RESULTS AND ANNOUNCES CLINICAL HOLD IN AXALIMOGENE FILOLISBAC PHASE 1/2 COMBINATION STUDY WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB)

BRIEF-Advaxis Prices $20.0 Mln Public Offering Of Common Stock

* ADVAXIS PRICES $20.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Advaxis Announces Proposed Public Offering Of Common Stock

* ADVAXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31

* ADVAXIS INC SAYS EXPECTS TO REPORT THAT IT HAD $59.4 MILLION OF CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JANUARY 31, 2018 - SEC FILING Source text: (http://bit.ly/2BHztlx) Further company coverage:

BRIEF-Advaxis Submits Conditional MAA For Second-Line Metastatic Cervical Cancer Treatment In European Union

* ADVAXIS SUBMITS CONDITIONAL MARKETING AUTHORIZATION APPLICATION FOR AXALIMOGENE FILOLISBAC FOR THE SECOND-LINE TREATMENT OF METASTATIC CERVICAL CANCER IN EUROPEAN UNION

Select another date: